|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�������� |
|
Ƥ������ |
| ��������������� | |
|
��־�� |
|
�˾� |
| PubMed | |
|
Article by |
|
Article by |
������������������Ƥ������Ӧ�ý�չ
��־��, �˾�
�ڶ���ҽ��ѧ����ҽԺƤ����, �Ϻ�200433
����������һ���������ƶ��������Լ�����ҩ��,���ж��ص����û���,��������������ʪ�ؽ������ơ���������ҩ�ѿ�ʼӦ����������Ƥ����������,���а�����м���������֯����(����Ǵ���Sjögren�ۺ���)�ȡ�Ϊ��,���ж��������ص������ʡ�ҩ������ѧ��ҩ����Ƽ�����������Ƥ�����е�Ӧ���������¡�
[2] Cherwinski HM, Byars N, Ballaron SJ, et al. Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res, 1995,44 (8):317-322.
[3] Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol, 1999, 93 (3):198-208.
[4] Thanos D, Maniatis T. NF-kappa B:a lesson in family values. Cell, 1995, 80(4):529-532.
[5] Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cy tokine gene regulation. Am J Respir Cell Mol Biol, 1997, 17(1):3-9.
[6] Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol, 1999, 162 (4):2095-2102.
[7] Siemasko K, Chong AS, Jack HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug le flunomide leads to a block in IgG1 production. J Immunol, 1998, 160 (4):1581-1588.
[8] Kaplan MJ. Leflunomide Aventis Pharma. Curr Opin Investig Drugs, 2001, 2(2):222-230.
[9] Mirmohammadsadegh A, Homey B, Abts HF, et al. Differential modu lation of pro-and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immu nomodulator leflunomide. Biochem Pharmacol, 1998, 55 (9):1523-1529.
[10] Reich K, Hummel KM, Beckmann I, et al. Treatment of severe psoria sis and psoriatic arthritis with leflunomide. Br J Dermatol, 2002,146 (2):335-336.
[11] Wallace D. Current and emerging lupus treatments. Am J Manag Care, 2001, 7(16 Suppl):S490-495.
[12] Fox RI. Sjogren's syndrome:current therapies remain inadequate for a common disease. Expert Opin Investig Drugs, 2000, 9 (9):2007-2016.
[13] Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide:a novel immunomodulatory agent. Arch Dermatol, 2000, 136 (10):1204-1205.
[14] Sanders S, Harisdangkul V. Leflunomide for the treatment of rheuma toid arthritis and autoimmunity. Am J Med Sci, 2002, 323 (4):190-193.
[15] Haberhauer G, Kittl EM, Dunky A, et al. Beneficial effects of le-flunomide in glucocorticoid-and methotrexate-resistant Takayasu's arte ritis. Clin Exp Rheumatol, 2001, 19(4):477-478.
[16] Affolter VK, Moore PF. Canine cutaneous and systemic histiocytosis:reactive histiocytosis of dermal dendritic cells. Am J Dermatopathol, 2000, 22(1):40-48.
[17] Jarman ER, Kuba A, Montermann E, et al. Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide. Clin Exp Immunol, 1999, 115(2):221-228.
[18] Zhu YI, Stiller MJ. Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol, 2000, 13(5):235-245.
[19] Furst DE. Leflunomide, mycophenolic acid and matrix metalloprotein ase inhibitors. Rheumatology (Oxford), 1999, 38 (Suppl 2):14-18.